Dr Wise on PSA Responses With Pasritamig Plus Docetaxel in mCRPC

“We know docetaxel has [an approximately] 45% PSA50 [response] rate, so [an 88.2% PSA50 response rate with the combination for patients with bone-only metastases] is substantially better. The pasritamig [monotherapy] PSA50 rate is approximately 35% to 37%, so we're seeing clear additive effect and potentially even some synergy [by adding docetaxel].”

David R. Wise, MD, PhD, an associate professor in the Department of Medicine and the Department of Urology at NYU Grossman School of Medicine, discussed the efficacy of pasritamig in combination with docetaxel for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Data from a phase 1b trial (NCT05818683) presented during the 2026 Genitourinary Cancers Symposium revealed that 64.7% of patients who received the combination (n = 51) experienced at least a 50% reduction of prostate-specific antigen levels (PSA50). Moreover, 39.2% of patients achieved a 90% or more reduction in PSA levels (PSA90). The PSA50 and PSA90 response rates among patients with bone-only metastases (n = 26) were 84.6% and 61.5%, respectively. These respective rates among patients with lymph node metastases with/without bone metastases (n = 8) were 75.0% and 25.0%.

Wise noted that patients with bone-only metastases (n = 17) who received the combination achieved a PSA50 response rate of 88.2%; the PSA90 response rate among these patients was 76.5%. Prior phase 3 data have shown that docetaxel monotherapy confers a PSA50 response rate of approximately 45% and pasritamig monotherapy has demonstrated a PSA50 response rate of approximately 35% to 37%, he added. Thus, early data from the phase 1b study have shown a clear additive effect and potentially even synergy between these 2 agents, he concluded.

Disclosures: Wise reported holding stock and other ownership interests with Doximity; receiving Honoria from OncLive and ScientiaCME; holding consulting or advisory roles with Bayer, Janssen, K36, OncoC4, and Pfizer; and receiving travel, accommodations, and expenses from Bayer and Pfizer.